Human 4-1BB / TNFRSF9 Protein, Mouse IgG2a Fc Tag, low endotoxin
分子別名(Synonym)
TNFRSF9,4-1BB,CD137,CDw137,ILA
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human 4-1BB Protein, Mouse IgG2a Fc Tag (41B-H5256) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # Q07011-1).
Predicted N-terminus: Leu 24
蛋白結(jié)構(gòu)(Molecular Characterization)
![1.jpg 1.jpg](/SupplyImg1/2025-02-07/6387453478170286944031411.jpg)
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 44.2 kDa. The protein migrates as 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg1/2025-02-07/6387453478997958995867652.jpg)
背景(Background)
4-1BB也被稱為CD137,腫瘤壞死因子受體超家族成員9(TNFRSF9),由淋巴細(xì)胞活化(ILA)誘導(dǎo),是腫瘤壞死因子(TNF)受體超家族的共刺激分子。CD137可以由活化的T細(xì)胞表達(dá),但在CD8上的表達(dá)程度大于CD4 T細(xì)胞。此外,在炎癥部位的樹突細(xì)胞、濾泡樹突細(xì)胞、自然殺傷細(xì)胞、粒細(xì)胞和血管壁細(xì)胞上發(fā)現(xiàn)了CD137的表達(dá)。CD137的最佳特征活性是其對(duì)活化T細(xì)胞的共刺激活性。CD137的交聯(lián)增強(qiáng)T細(xì)胞增殖、IL-2分泌存活和細(xì)胞溶解活性。此外,它可以增強(qiáng)免疫活性,消除小鼠的腫瘤。當(dāng)TCR/CD3復(fù)合物結(jié)合時(shí),CD137可以增強(qiáng)活化誘導(dǎo)的T細(xì)胞凋亡。此外,4-1BB/4-1BBL共刺激途徑已被證明可以增強(qiáng)對(duì)幾種病毒的次級(jí)CTL反應(yīng),同時(shí)增強(qiáng)抗腫瘤免疫。因此,4-1BB是人類癌癥免疫治療的一種有前景的候選物。CD137已被證明與TRAF2相互作用。
關(guān)鍵字: 4-1BB;4-1BB蛋白;4-1BB重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。